Retatrutide vs Semaglutide
Side-by-side literature comparison of a triple GLP-1 / GIP / glucagon receptor agonist (Retatrutide) and a single-receptor GLP-1 agonist (Semaglutide) at the receptor-pharmacology level.
Side-by-Side Attributes
Objective data pulled from the published peptide literature. For research context only — not efficacy or performance claims.
| Attribute | Retatrutide | Semaglutide |
|---|---|---|
| Class | Triple GLP-1 / GIP / glucagon receptor agonist | GLP-1 receptor monoagonist |
| Receptor targets | GLP-1R + GIPR + GCGR | GLP-1R |
| Length | 39 amino acids | 31 amino acids |
| Molecular Weight | ~4731 Da | ~4113.6 Da |
| Lipid modification | C20 fatty diacid side chain | C18 fatty diacid on Lys26 |
| Parent sequence lineage | Chimeric backbone drawing on GLP-1, GIP, and glucagon | Modified GLP-1(7-37) analogue |
| First described (public literature) | ~2022 (Eli Lilly) | ~2012 (Novo Nordisk) |
| In-vitro half-life (preclinical model reports) | Reported extended vs native peptides across all three receptor families | Reported extended vs native GLP-1 |
| Synthesis complexity | SPPS with orthogonal protection + on-resin lipidation | SPPS with on-resin lipidation of Lys side chain |
| Endotoxin release spec (BioInfinity) | < 0.5 EU/mg by LAL | < 0.5 EU/mg by LAL |
| Third-party COA lab (BioInfinity) | Verum Analytics, Switzerland | Verum Analytics, Switzerland |
Literature Context
Retatrutide is the most receptor-broad member of the current published incretin-family research peptide corpus, engaging three receptors — GLP-1R, GIPR, and GCGR (glucagon receptor) — in a single molecule. Semaglutide, by comparison, is a single-receptor GLP-1R monoagonist. The pharmacological gap between the two compounds is therefore twofold: the addition of GIPR agonism (also present in Tirzepatide) and the further addition of GCGR agonism (unique to Retatrutide in the current literature).
From a structural standpoint, Retatrutide's chimeric backbone draws sequence features from three different native peptides (GLP-1, GIP, and glucagon), which is what enables the multi-receptor pharmacology reported in the 2022+ literature. Semaglutide's backbone is a comparatively conservative modification of the native GLP-1(7-37) sequence.
Both compounds are common tool peptides in in-vitro receptor-pharmacology work. Neither is FDA-approved for any indication under BioInfinity supply; both are supplied strictly for laboratory research.
Research Contexts in the Literature
Overlapping
- GLP-1R binding & activation assays
- cAMP signalling pathway research
- β-arrestin recruitment studies
- Preclinical rodent metabolic-model literature
- Peptide-lipidation & PK in-vitro research
Retatrutide only
- GIP receptor pharmacology in-vitro
- GCGR (glucagon receptor) cross-reactivity studies
- Triple-agonist chimeric-peptide design literature
- Multi-receptor functional-selectivity research
Semaglutide only
- GLP-1R monoagonist selectivity assays
- GLP-1(7-37) analogue structure-activity relationship literature
- GLP-1R desensitization / recycling kinetics research
All products supplied by BioInfinity are for in-vitro laboratory research use only. Not FDA-approved. Not intended for human or veterinary use. This page is a literature summary — not medical, dosing, or usage guidance.